Relatively Lower FT3 Levels Are Associated with Impaired Quality of Life in Levothyroxine-Treated Patients with Hashimoto Thyroiditis

Table 1

Comparison of clinical characteristics and ThyPRO scores between the two groups.

Variable	Control group, n = 64	Well-controlled group, n = 69	P
Age, years	45.94 ± 12.76	45.10 ± 12.24	0.700
Female/male, n	60/4	61/8	0.282
BMI, kg/m^2	23.87 ± 3.86	23.81 ± 3.91	0.929
TT3, ng/ml	1.16 (1.01, 1.32)	1.03 (0.94, 1.26)	0.006
TT4, μg/dl	8.90 (7.63, 10.08)	8.55 (7.70, 9.68)	0.537
FT3, pg/ml	3.13 ± 0.27	2.97 ± 0.27	0.001
FT4, ng/dl	1.21 ± 0.16	1.28 ± 0.19	0.016
TSH, μIU/ml	2.63 ± 0.98	2.55 ± 1.13	0.692
TPOAb, U/ml	785.65 (164.93, 1855.28)	1156.7 (118.3, 3174.5)	0.447
TGAb, U/ml	223.2 (84.23, 400.2)	148.0 (79.63, 481.58)	0.860
ThyPRO
Goiter symptoms	2 (2, 2)	10 (10, 15)	<0.001
Hyperthyroid symptoms	8 (2, 18)	18 (8, 23)	<0.001
Hypothyroid symptoms	6.25 (0, 6.25)	25 (12,5, 37.5)	<0.001
Eye symptoms	8 (1, 8)	14 (8, 22.5)	<0.001
Tiredness	33 (25, 42)	42 (33, 50)	0.021
Cognitive complaints	1 (1, 14)	21 (7, 37)	<0.001
Anxiety	1 (1, 1)	10 (1, 26)	<0.001
Depression	29 (22, 29)	29 (22, 37)	0.018
Emotional susceptibility	28 (28, 36)	36 (28, 52)	0.009
Impaired social life	0 (0, 0)	17 (0, 25)	<0.001
Impaired daily life	0 (0, 0)	0 (0, 15)	<0.001
Cosmetic complaints	1 (1, 1)	1 (1, 28)	<0.001
Overall quality of life impact	0 (0, 0)	25 (0, 25)	<0.001
Composite scale	14.77 (13.64, 17.05)	23.86 (18.75, 31.82)	<0.001

Data are means ± s.d. unless indicated otherwise. Bold indicates P value <0.05.